Inhibition of tumor angiogenesis

"Inhibition of tumor angiogenesis" describes a **therapeutic strategy or process, not a specific molecular target**. Angiogenesis is the formation of new blood vessels, and tumors exploit this process to secure a blood supply, supporting their growth and metastatic potential[10][7][4]. Numerous **molecular targets** are involved in this process—such as vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), fibroblast growth factors (FGFs), platelet-derived growth factors (PDGFs), chemokine receptors (CXCR2), matrix metalloproteinases (MMPs), and many others[2][9][3]. Drugs designed to inhibit angiogenesis, called anti-angiogenic agents or angiogenesis inhibitors, work by interfering with these specific molecular actors to block the formation of blood vessels in tumors[10][7][4].\n\nWhile inhibition of tumor angiogenesis is a critical concept and therapeutic goal in oncology, it is **not itself a molecule, protein, or receptor**, but rather an umbrella term describing the inhibition of multiple potential targets and pathways involved in the angiogenic process[10][2][4]. Therefore, it is not an appropriate entry for a molecular target database and should be mapped to one or more specific molecular entities (e.g., "Vascular endothelial growth factor A receptor", "Tie2 receptor", etc.) for structured annotation.

Other names

Anti-angiogenic activityAnti-angiogenesisInhibition of angiogenesis